All News
TheDaoIndex KDAO2011 ( View Tweet)
Pulmonary Manifestations of Rheumatic Disease in Asymptomatic Patients
In clinical practice, pulmonary manifestations of rheumatic medical diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and peripheral spondyloarthritis (pSpA) are typically not screened for upon diagnosis of a rheumatic disease in patients without any signs or symptoms suggest
Read ArticlePregnancy Updates That Will Change The Way I Practice
ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification.
Read ArticleACR Convergence Preview (11.10.2023)
Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting.
Read ArticleLate Should Not Be Less (11.3.2023)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.
Read ArticleOral Surveillance Study Alters Practice at VA
Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the Veterans Affairs (VA) health system, researchers found.
Read ArticleCardiovascular and Venous Thromboembolic Risk With JAK Inhibitor Treatment of Skin Disorders
A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo
Read ArticleSubcutaneous Biosimilars? (10.27.2023)
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
Read Article